These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9469635)

  • 1. Antithrombin III in hematopoietic stem cell transplantation.
    Haire WD
    Semin Thromb Hemost; 1997; 23(6):591-601. PubMed ID: 9469635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation.
    Haire WD; Ruby EI; Stephens LC; Reed E; Tarantolo SR; Pavletic ZS; Bierman PJ; Bishop M; Kessinger A; Vose J; Armitage JO
    Biol Blood Marrow Transplant; 1998; 4(3):142-50. PubMed ID: 9923412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The multiple organ dysfunction syndrome in cancer patients undergoing hematopoietic stem cell transplantation.
    Haire WD
    Semin Thromb Hemost; 1999; 25(2):223-37. PubMed ID: 10357090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] ].
    Baudo F; de Cataldo F
    Minerva Anestesiol; 2000 Nov; 66(11 Suppl 1):3-23. PubMed ID: 11213542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation.
    Morris JD; Harris RE; Hashmi R; Sambrano JE; Gruppo RA; Becker AT; Morris CL
    Bone Marrow Transplant; 1997 Nov; 20(10):871-8. PubMed ID: 9404929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors predicting morbidity following hematopoietic stem cell transplantation.
    Gordon B; Haire W; Ruby E; Kotulak G; Stephens L; Kessinger A; Armitage J
    Bone Marrow Transplant; 1997 Mar; 19(5):497-501. PubMed ID: 9052918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early intervention with antithrombin III therapy to prevent progression of hepatic venoocclusive disease.
    Peres E; Kintzel P; Dansey R; Baynes R; Abidi M; Klein J; Ibrahim RB; Abella E
    Blood Coagul Fibrinolysis; 2008 Apr; 19(3):203-7. PubMed ID: 18388499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Are there certified indications for the use of antithrombin III in intensive care].
    Kulka PJ; Tryba M; Lange S
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2001 Mar; 36(3):143-53. PubMed ID: 11324345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure.
    Eisele B; Lamy M
    Semin Thromb Hemost; 1998; 24(1):71-80. PubMed ID: 9515782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombin III in animal models of sepsis and organ failure.
    Dickneite G
    Semin Thromb Hemost; 1998; 24(1):61-9. PubMed ID: 9515781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose of intravenous antithrombin III without heparin in the treatment of disseminated intravascular coagulation and organ failure in four children.
    Fuse S; Tomita H; Yoshida M; Hori T; Igarashi C; Fujita S
    Am J Hematol; 1996 Sep; 53(1):18-21. PubMed ID: 8813091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity-guided antithrombin III therapy in severe surgical sepsis: efficacy and safety according to a retrospective data analysis.
    Moubarak P; Zilker S; Wolf H; Hofner B; Kneib T; Küchenhoff H; Jauch KW; Hartl WH
    Shock; 2008 Dec; 30(6):634-41. PubMed ID: 18520701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-inflammatory properties of antithrombin III: new therapeutic implications.
    Okajima K; Uchiba M
    Semin Thromb Hemost; 1998; 24(1):27-32. PubMed ID: 9515777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombin III in Sepsis. New evidences and open questions.
    Ostermann H
    Minerva Anestesiol; 2002 May; 68(5):445-8. PubMed ID: 12029261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity.
    Ibrahim RB; Peres E; Dansey R; Abidi MH; Abella EM; Klein J
    Ann Pharmacother; 2004 Jun; 38(6):1053-9. PubMed ID: 15113990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of antithrombin III in critical patients in obstetrics.
    Mangione S; Giarratano A
    Minerva Anestesiol; 2002 May; 68(5):449-53. PubMed ID: 12029262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombin III. Key factor in extracorporeal circulation.
    Ranucci M
    Minerva Anestesiol; 2002 May; 68(5):454-7. PubMed ID: 12029263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of antithrombin concentrate during autologous hematopoietic stem cell transplantation.
    Haire WD; Stephens LC; Kotulak GD; Ruby EI; Gordon BG
    Bone Marrow Transplant; 1995 Apr; 15(4):505-7. PubMed ID: 7655373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.
    Warren BL; Eid A; Singer P; Pillay SS; Carl P; Novak I; Chalupa P; Atherstone A; Pénzes I; Kübler A; Knaub S; Keinecke HO; Heinrichs H; Schindel F; Juers M; Bone RC; Opal SM;
    JAMA; 2001 Oct; 286(15):1869-78. PubMed ID: 11597289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.